secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2026-09-28T12:53:40+00:00
Accession:  0001140361-26-037767
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Lifecore Biomedical to be acquired by Webster Equity affiliates for $6.28/share cash plus CVR
--------------------------------------------------------------------------------

- Merger Agreement dated Sept. 27, 2026: Merger Sub merges into Lifecore; holders receive $6.28 per share in cash plus one CVR; no financing condition.
- Financing: $400M Webster equity, $115M term loans, $30M revolver, $35M Alcon term loan; closing conditioned on Alcon supply/manufacturing agreements, including Amendment No. 3 dated Sept. 24, 2026.
- CVR payments: $30M if 2028 revenue is at least $120M from non-Alcon customers and $54M from Alcon or $174M total; $45M for 2029; $85M for 2030 EBITDA of at least $120M.
- Termination fees are $7,468,287 go-shop, $9,957,716 company, and $16,181,288 reverse; outside date June 27, 2027, extendable to Sept. 27, 2027 if HSR is pending.
- Wynnefield and Legion stockholders, tied to directors Nelson Obus and Christopher S. Kiper, signed voting support agreements covering their Lifecore shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000114036126037767/0001140361-26-037767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000114036126037767/ef20082009_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-037767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer